Your session is about to expire
← Back to Search
Virus Therapy
VIR-2482 (Dose 1) for Flu
Phase 2
Waitlist Available
Research Sponsored by Vir Biotechnology, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to week 84
Awards & highlights
Summary
This trial tested a new drug to see if it can prevent the flu in healthy adults 18-65, with no existing risk factors.
Eligible Conditions
- Flu
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to week 84
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to week 84
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Occurrence of adverse events (AEs)
Occurrence of adverse events of special interest (AESI)
Occurrence of serious adverse events (SAEs)
+3 moreSecondary outcome measures
Proportion of participants with CDC-defined ILI with confirmed influenza A (by RT-PCR)
Proportion of participants with WHO-defined ILI with confirmed influenza A (by RT-PCR)
Trial Design
3Treatment groups
Experimental Treatment
Placebo Group
Group I: VIR-2482 (Dose 2)Experimental Treatment1 Intervention
Group II: VIR-2482 (Dose 1)Experimental Treatment1 Intervention
Group III: PlaceboPlacebo Group1 Intervention
Find a Location
Who is running the clinical trial?
Vir Biotechnology, Inc.Lead Sponsor
27 Previous Clinical Trials
10,279 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You are between the ages of 18 and 65 years.You have taken any experimental medication within the last 90 days or within 5 half-lives of that medication.You have a medical history or symptoms that put you at a high risk of developing complications from the flu.You have a fever and may or may not have respiratory symptoms.You had a serious allergic reaction in the past that caused hives, swelling, or difficulty breathing.
Research Study Groups:
This trial has the following groups:- Group 1: VIR-2482 (Dose 1)
- Group 2: Placebo
- Group 3: VIR-2482 (Dose 2)
Awards:
This trial has 0 awards, including:Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger